These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38703743)

  • 1. Off-label higher doses of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Safety and tolerability.
    Levy DM; Arush OB; Carmi L; Wetzler AJ; Zohar J
    Compr Psychiatry; 2024 Aug; 133():152486. PubMed ID: 38703743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
    Maina G; Albert U; Salvi V; Bogetto F
    J Clin Psychiatry; 2004 Oct; 65(10):1365-71. PubMed ID: 15491240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
    J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluvoxamine: new indication. No progress in obsessive-compulsive disorder.
    Prescrire Int; 2004 Oct; 13(73):163-5. PubMed ID: 15499694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.
    Bergeron R; Ravindran AV; Chaput Y; Goldner E; Swinson R; van Ameringen MA; Austin C; Hadrava V
    J Clin Psychopharmacol; 2002 Apr; 22(2):148-54. PubMed ID: 11910259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
    Carpenter LL; McDougle CJ; Epperson CN; Price LH
    Drug Saf; 1996 Aug; 15(2):116-34. PubMed ID: 8884163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sertraline and obsessive compulsive disorder: new indication. Limited assessment.
    Prescrire Int; 2000 Aug; 9(48):112-3. PubMed ID: 11067720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
    Todorov C; Freeston MH; Borgeat F
    Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.
    Ninan PT; Koran LM; Kiev A; Davidson JR; Rasmussen SA; Zajecka JM; Robinson DG; Crits-Christoph P; Mandel FS; Austin C
    J Clin Psychiatry; 2006 Jan; 67(1):15-22. PubMed ID: 16426083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    Psychopharmacol Bull; 1996; 32(1):167-73. PubMed ID: 8927668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
    Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
    Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder.
    Coskun M; Zoroglu S
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):297-300. PubMed ID: 19519265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
    Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
    J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.
    Rasmussen S; Hackett E; DuBoff E; Greist J; Halaris A; Koran LM; Liebowitz M; Lydiard RB; McElroy S; Mendels J; O'Connor K
    Int Clin Psychopharmacol; 1997 Nov; 12(6):309-16. PubMed ID: 9547132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.